Milacemide
From Wikipedia, the free encyclopedia
 |
|
| Names | |
|---|---|
| IUPAC name
2-(Pentylamino)acetamide[1]
|
|
| Identifiers | |
76990-56-2  |
|
| ChEMBL | ChEMBL75838 |
| ChemSpider | 48376 |
| Jmol interactive 3D | Image Image |
| MeSH | milacemide |
| PubChem | 53569 |
| UNII | 0HXT24RECU |
|
|
|
|
| Properties | |
| C7H16N2O | |
| Molar mass | 144.22 g·mol−1 |
| log P | 0.754 |
| Related compounds | |
|
Related compounds
|
Tricine |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
| Infobox references | |
Milacemide (INN)[2] is an MAO-B inhibitor and glycine prodrug.[3] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.[4] Early clinical trials did not show positive results however,[3] and the drug is now abandoned.
References[edit]
- ^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
- ^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
- ^ a b Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.". Journal of the American Geriatrics Society 40 (5): 503–6. PMID 1634705.
- ^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
